Photo has been used for illustrative purposes.
Complete results from the research, which was carried out by US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical periodical the New England Journal of Medicine.
The United States authorised the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit.
The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalised COVID-19 patients compared to a placebo in clinical tests on just over a thousand patients across 10 countries.
On April 29, NIAID director Anthony Fauci, who has become the US government's trusted face on the coronavirus pandemic, said preliminary evidence indicated remdesivir had a "clear-cut, significant and positive effect in diminishing the time to recovery."
The National Institutes of Health, of which the NIAID is a part, said Friday in a statement online that investigators found "remdesivir was most beneficial for hospitalised patients with severe disease who required supplemental oxygen."
But the authors of the trial wrote that the drug did not prevent all deaths.
"Given high mortality despite the use of remdesivir, it is clear that treatment with an anti-viral drug alone is not likely to be sufficient," they said.
About 7.1 per cent of patients given remdesivir in the trial group died within 14 days — compared with 11.9 per cent in the placebo group.
However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug.
The global death toll from the virus surged past 106,000 on Saturday, with the United States quickly becoming the epicentre of the pandemic that first emerged in China late last year.
At the climax of Holy Week for the planet's two billion-plus Christians, congregations were shuttered at home to avoid spreading the pathogen that has infected at least 1.7 million worldwide.
The majority of the world's population remains susceptible to COVID-19 and there is a long road to travel as the risk remains high, the chief of the World health Organization (WHO) said.
Shortages of critical equipment led to fierce competition among buyers from Europe, the US and elsewhere. A regional leader in Paris described the scramble to find masks a “worldwide treasure hunt.” Gov. Andrew Cuomo warned that New York could run out of ventilators in six days.
Rihanna‘s fashion and beauty brands stopped operating on Blackout Tuesday in a statement of solidarity with the Black Lives Matter movement.
Barcelona has become one of the world's top tourist destinations thanks to its Mediterranean climate, mesmerizing architecture and liberal way of life.
Universal Orlando is only reopening at 35 percent capacity and has launched a system of virtual lines in which space can be reserved, to avoid queues and crowds.